Medicure Inc (TSXV:MPH)(OTC:MCUJF), a pharmaceutical company, announced yesterday its financial results for the quarter ended 30 June 2019.
The company reported adjusted EBITDA for the quarter ended 30 June 2019 at USD103,000 compared to adjusted EBITDA of USD882,000 for the quarter ended 30 June 2018.
The firm posted net loss for the quarter ended 30 June 2019 at USD957,000 compared to net income of USD1.6m for the quarter ended 30 June 2018.
Net loss for the six months ended 30 June 2019 was USD3.7m or USD0.24 per share. This compares to net income of USD3.0m or USD0.19 per share for the six months ended 30 June 2018.
Acerus and Aytu Bioscience to Co-promote Natesto in the United States
Amgen reports financial results for Q2 2019
Pfizer to integrate Upjohn with Mylan to establish new global pharmaceutical company
Neurocrine Biosciences reports half-year ended 30 June 2019 financial results
Thermo Fisher Scientific reports financial results for Q2 2019
Veloxis Pharmaceuticals revises 2019 outlook
NANOBIOTIX collects revenues of EUR31.9,000 for Q2 2019
Seattle Genetics incurs net loss of USD79.2m in Q2 2019
Baxter's board announces USD0.22 per share dividend pay order
Johnson & Johnson declares dividend of USD0.95 per share for Q3 2019
Sun Pharma Launches Ezallor Sprinkle in the US for People Who Have Difficulty Swallowing
PanTheryx Aims to End Diarrheal Disease in Cambodia
CCA Industries Inc swings to income of USD349,320 for Q2 2019
Oncimmune Holdings signs commercial collaboration with R-Pharm JSC